Progressive Vitiligo: Anifrolumab and Phototherapy Study

We are investigating whether combining anifrolumab with phototherapy helps adults with progressive vitiligo regain skin color better than phototherapy alone. The study will also assess the safety and tolerability of this new treatment approach.

6-12 monthsEfficacy phase (II)Standard MedicinesInjectionAllergologyDermatology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Saphnelo
Saphnelo is a medicine used to treat moderate to severe lupus in adults by reducing inflammation caused by the immune system.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Anifrolumab
Anifrolumab is a substance that blocks interferon signals to reduce immune-driven inflammation in people with systemic lupus erythematosus.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centre Hospitalier Universitaire De Bordeaux
Dermatologie de l’Adulte et de l’Enfant
Bordeaux, France
Hospices Civils De Lyon
Dermatologie, vénérologie, allergologie, dermatologie esthétique
Bron, France
Centre Hospitalier Le Mans
Dermatologie
Coulaines, France
Sponsor: Centre Hospitalier Universitaire De Bordeaux
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.